AT290528B - Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen - Google Patents

Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Info

Publication number
AT290528B
AT290528B AT1082569A AT1082569A AT290528B AT 290528 B AT290528 B AT 290528B AT 1082569 A AT1082569 A AT 1082569A AT 1082569 A AT1082569 A AT 1082569A AT 290528 B AT290528 B AT 290528B
Authority
AT
Austria
Prior art keywords
pyrazin
imidazo
chloro
ones
salts
Prior art date
Application number
AT1082569A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of AT290528B publication Critical patent/AT290528B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT1082569A 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen AT290528B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77747868A 1968-11-20 1968-11-20

Publications (1)

Publication Number Publication Date
AT290528B true AT290528B (de) 1971-06-11

Family

ID=25110370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT1082569A AT290528B (de) 1968-11-20 1969-11-19 Verfahren zur Herstellung von neuen 5-NR<1>R<2>-6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen und ihren Salzen

Country Status (10)

Country Link
US (1) US3567725A (de)
AT (1) AT290528B (de)
BE (1) BE741910A (de)
BR (1) BR6914329D0 (de)
DE (2) DE1957711A1 (de)
FR (1) FR2035817B1 (de)
GB (1) GB1246006A (de)
IL (1) IL33336A0 (de)
NL (1) NL6915957A (de)
ZA (1) ZA698081B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810933D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) * 1987-05-26 1988-06-15 Ici America Inc Amides
US5705585A (en) 1993-06-30 1998-01-06 Arqule, Inc. Aminimide-containing molecules and materials as molecular recognition agents
US7034110B2 (en) * 1994-01-05 2006-04-25 Arqule, Inc. Method of identifying chemical compounds having selected properties for a particular application
AU704878B2 (en) * 1994-01-05 1999-05-06 Arqule, Inc. Method of making polymers having specific properties
US5734082A (en) * 1994-10-20 1998-03-31 Arqule Inc. Hydroxyethyl aminimides
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
AU5438796A (en) * 1995-04-06 1996-10-23 Arqule, Inc. Method for rapid purification, analysis and characterization of collections of chemical compounds
US5962412A (en) * 1996-06-10 1999-10-05 Arqule, Inc. Method of making polymers having specific properties
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP3549940A1 (de) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmazeutische formulierungen von 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)-pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (de) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Verfahren zur behandlung von krebs anhand einer tor-kinasehemmerkombinationstherapie
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Also Published As

Publication number Publication date
DE1957711A1 (de) 1970-06-18
FR2035817A1 (de) 1970-12-24
BE741910A (de) 1970-05-19
NL6915957A (de) 1970-05-22
DE1965989A1 (de) 1971-02-18
FR2035817B1 (de) 1973-01-12
US3567725A (en) 1971-03-02
GB1246006A (en) 1971-09-15
BR6914329D0 (pt) 1973-02-22
IL33336A0 (en) 1970-01-29
ZA698081B (en) 1971-07-28

Similar Documents

Publication Publication Date Title
AT294113B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-2H-1,2-benzothiazin-1,1-dioxyden und ihren Salzen
AT295511B (de) Verfahren zur Herstellung von neuen Phenoxyaminopropanolderivaten und ihren Salzen
AT304535B (de) Verfahren zur Herstellung von neuen 2-(Thienyl-3&#39;-amino)-1,3-diazacycloalkenen-(2) und ihren Salzen
AT321277B (de) Verfahren zur Herstellung von neuen 1,3-Diphenyl-propan-1-onen und ihren Salzen
AT288378B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT303053B (de) Verfahren zur Herstellung von neuen 1,1,1-Trichloräthan-Derivaten und ihren Salzen
AT291250B (de) Verfahren zur Herstellung von neuen 5-NR&lt;1&gt;R&lt;2&gt; -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen
AT286290B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT269166B (de) Verfahren zur Herstellung von neuen p,p&#39;-Dialkanoyldiphenylharnstoff-bis-guanylhydrazonen und ihren Salzen
AT299193B (de) Verfahren zur Herstellung von neuen Imidazolidinochinalinderivaten und ihren Salzen
AT289789B (de) Verfahren zur Herstellung von neuen 1,2,5-Thiadiazolderivaten und ihren Salzen
AT315862B (de) Verfahren zur Herstellung von neuen Diazepinderivaten und ihren Additionssalzen
AT286289B (de) Verfahren zur Herstellung von neuen Pyridoindolderivaten und ihren Salzen
AT287694B (de) Verfahren zur Herstellung von neuen Imidazolindinderivaten und ihren Salzen
AT295756B (de) Verfahren zur Herstellung von neuen Steroid-17&amp;alpa;,21-orthocarbonaten
AT288416B (de) Verfahren zur Herstellung von neuen Benzoxazinderivaten und ihren Salzen
AT303716B (de) Verfahren zur Herstellung von neuen basischen Dithienylmethanderivaten und ihren Salzen
AT315844B (de) Verfahren zur Herstellung von neuen basisch substituierten 2,3,7,8-Tetrahydro-1H-chino[1,8-ab][1]benzazepinen und von ihren Salzen
AT286299B (de) Verfahren zur herstellung von neuen 1-substituierten 6,7-dimethoxy-isochinolinen und ihren salzen
AT304487B (de) Verfahren zur Herstellung von neuen 9-Aminoalkyl-9,10-dihydro-9,10-äthano-anthrazenen und ihren Salzen
AT297727B (de) Verfahren zur Herstellung von neuen 3-Aryl-benzazinen und ihren Salzen
AT303749B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-oxathiazin-4-on-2,2-dioxyden und ihren Salzen
AT299196B (de) Verfahren zur Herstellung von neuen 5-Aryl-3H-1,2,4-dithiazolen und ihren Salzen
AT285620B (de) Verfahren zur Herstellung von neuen 1,2-Oxazinderivaten und ihren Salzen
AT294810B (de) Verfahren zur Herstellung von neuen, substituierten Flourenyloxy- und Fluorenylthioessigsäuren und ihren Salzen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee